Search Results Search Sort by RelevanceMost Recent Health Law Oct 2020 Effects of Substance Use Disorder Criminalization on American Indian Pregnant Individuals Rachel Simon, MD, Jennifer Giroux, MD, MPH, and Julie Chor, MD, MPH Clinicians must advocate for decriminalization of SUDs during pregnancy and for improving access to comprehensive, evidence-based care. AMA J Ethics. 2020;22(10):E862-867. doi: 10.1001/amajethics.2020.862. Case and Commentary Oct 2006 Coping with a Child's Conduct Disorder Sharon Hirsch, MD and Rebecca Sheffield Virtual Mentor. 2006;8(10):654-658. doi: 10.1001/virtualmentor.2006.8.10.ccas3-0610. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777. Case and Commentary Aug 2017 Should Clinicians Medicate against Structural Violence? Potential Iatrogenic Risks and the Need for Social Interventions Lauren E. Hock, MD and Niranjan S. Karnik, MD, PhD Risks of off-label medication to treat aggression should be balanced with consequences of not responding to social factors. AMA J Ethics. 2017;19(8):753-761. doi: 10.1001/journalofethics.2017.19.8.ecas2-1708. Case and Commentary Jun 2011 Herbal Supplements as Placebos Valerie Jones, MD Even if a placebo is safe, it should not be employed as a way of mollifying patients or glossing over underlying causes of illness. Virtual Mentor. 2011;13(6):354-358. doi: 10.1001/virtualmentor.2011.13.6.ccas3-1106.
Health Law Oct 2020 Effects of Substance Use Disorder Criminalization on American Indian Pregnant Individuals Rachel Simon, MD, Jennifer Giroux, MD, MPH, and Julie Chor, MD, MPH Clinicians must advocate for decriminalization of SUDs during pregnancy and for improving access to comprehensive, evidence-based care. AMA J Ethics. 2020;22(10):E862-867. doi: 10.1001/amajethics.2020.862.
Case and Commentary Oct 2006 Coping with a Child's Conduct Disorder Sharon Hirsch, MD and Rebecca Sheffield Virtual Mentor. 2006;8(10):654-658. doi: 10.1001/virtualmentor.2006.8.10.ccas3-0610.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Case and Commentary Aug 2017 Should Clinicians Medicate against Structural Violence? Potential Iatrogenic Risks and the Need for Social Interventions Lauren E. Hock, MD and Niranjan S. Karnik, MD, PhD Risks of off-label medication to treat aggression should be balanced with consequences of not responding to social factors. AMA J Ethics. 2017;19(8):753-761. doi: 10.1001/journalofethics.2017.19.8.ecas2-1708.
Case and Commentary Jun 2011 Herbal Supplements as Placebos Valerie Jones, MD Even if a placebo is safe, it should not be employed as a way of mollifying patients or glossing over underlying causes of illness. Virtual Mentor. 2011;13(6):354-358. doi: 10.1001/virtualmentor.2011.13.6.ccas3-1106.